NCCN Receives $1 Million Grant From Genentech

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

PHILADELPHIA--The NCCN (National Comprehensive Cancer Network) has received a $1 million unrestricted grant from Genentech, Inc. The grant, provided over a 2-year period, will be used to support the development and expansion of the NCCN Oncology Outcomes Database with emphasis on breast cancer and non-Hodgkin’s lymphoma.

PHILADELPHIA--The NCCN (National Comprehensive Cancer Network) has received a $1 million unrestricted grant from Genentech, Inc. The grant, provided over a 2-year period, will be used to support the development and expansion of the NCCN Oncology Outcomes Database with emphasis on breast cancer and non-Hodgkin’s lymphoma.

The NCCN, established in 1995, is a coalition of 17 leading US cancer centers. To date, the network has developed Oncology Practice Guidelines, which are steadily becoming the standard for clinical and coverage policy in cancer care. To date, NCCN guidelines are available for 93% of all cancers.

The NCCN Oncology Outcomes Database was launched recently in an effort to provide patients, physicians, and payers with a constant flow of data and information to facilitate optimal decision-making in the treatment of all cancers.

"This agreement with Genentech affirms the critical importance of the NCCN’s Oncology Outcomes Database, as well as NCCN’s commitment to the highest quality of cancer care through excellence in research and the collection and analysis of outcomes data," said

NCCN chief executive officer William T. McGivney, PhD, commented, "NCCN implementation of practice guidelines through performance measurement establishes the model for continuous quality improvement in cancer care."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content